• Industry veteran with over 25 years’ experience will continue to advance the company culture and grow the capabilities of Arcutis’ workforce
  

WESTLAKE VILLAGE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer (CHRO), effective immediately. Mr. Tucker joined Arcutis in July 2020 as executive director and head of human resources and was promoted to vice president of human resources in March 2022. Prior to joining Arcutis, he held leadership roles in human resources and employee management at multiple pharmaceutical companies including Atara Biotherapeutics, Sienna Biopharmaceuticals, and Kythera.

“I am delighted to name Todd as our first CHRO as we continue to build our corporate culture, and attract, grow, and retain our people,” said Frank Watanabe, president, and CEO of Arcutis. “This promotion is well-deserved recognition of his outstanding performance at Arcutis leading all our people-centered programs and initiatives. Under his leadership, we have grown dramatically, evolved from a clinical-stage company to a commercial-stage company, and enhanced the core competencies and productivity of our workforce. I look forward to seeing him continue to excel in his role as we strengthen our commercial operations and build the leading innovation-driven medical dermatology company.”

“I am excited to continue my journey at Arcutis, leading our human resources activities and creating the best work environment for each and every one of our employees,” said Mr. Tucker. “As we continue to grow as a leader in the dermatology space, I am proud to be part of a trailblazing leadership team here at Arcutis.”

Mr. Tucker joined Arcutis from Atara Biotherapeutics, where he led the compensation and benefits department. Prior, he functioned as senior director and head of human resources at Sienna Biotherapeutics, where he established and led the human resources function as the company transitioned from a private to a publicly traded company. Before joining Sienna, he was the associate director of human resources at Kythera, where he was instrumental in helping the company transition to a commercial-stage company. Mr. Tucker started his career at Amgen, where he held roles of increasing responsibility.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including two FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and X.

Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential to build the leading innovation-driven medical dermatology company. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
asheldon@arcutis.com

Investors
Latha Vairavan, Vice President, Finance and Investor Relations
lvairavan@arcutis.com

Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com